Ohr To Evaluate Strategic Alternatives As MAKO Study Fails To Meet Endpoint

(RTTNews) - Ohr Pharmaceutical, Inc. (OHRP) reported topline data from the MAKO study which did not meet its primary efficacy endpoint. Based on the results, the company said it intends to evaluate strategic alternatives to maximize shareholder value.

The MAKO study was a multi-center, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of squalamine in combination with Lucentis injections for the treatment of wet age-related macular degeneration. The primary efficacy endpoint was the mean visual acuity gain at nine months, using a mixed-effects model for repeated measures analysis. Subjects receiving squalamine combination therapy achieved a mean gain of 8.33 letters from baseline versus 10.58 letters from baseline with Lucentis monotherapy.